Skip to main content
Download PDF

Short- and long-term mortality in patients with urosepsis caused by Escherichia coli susceptible and resistant to 3rd generation cephalosporins

BMC Infectious Diseases volume 22, Article number: 571 (2022) Cite this article

Abstract

Background

The aim of this study was to compare short- and long-term mortality among patients with urosepsis caused by Escherichia coli susceptibile (EC-SC) and resistant (EC-RC) to 3rd generation cephalosporins.

Methods

A retrospective cohort study that included all patients with E. coli urosepsis admitted to a 700-bed hospital from January 2014 until December 2019. Mortality up to 30 days, 6 months and 1 year was assessed using logistic multivariate regression analysis and Cox regression analysis.

Results

A total of 313 adult were included, 195 with EC-SC and 118 patients with EC-RC. 205 were females (74%), mean age was 79 (SD 12) years. Mean Charlson score was 4.93 (SD 2.18) in the EC-SC group and 5.74 (SD 1.92) in the EC-RC group. Appropriate empiric antibiotic therapy was initiated in 245 (78.3%) patients, 100% in the EC-SC group but only 42.5% in the EC-RC group. 30-day mortality occurred in 12 (6.3%) of EC-SC group and 15 (12.7%) in the EC-RC group. Factors independently associated with 30-day mortality were Charlson score, Pitt bacteremia score, fever upon admission and infection with a EC-RC. Appropriate antibiotic therapy was not independently associated with 30-day mortality. Differences in mortality between groups remained significant one year after the infection and were significantly associated with the Charlson co-morbidity score.

Conclusions

Mortality in patients with urosepsis due to E. coli is highly affected by age and comorbidities. Although mortality was higher in the EC-RC group, we could not demonstrate an association with inappropriate empirical antibiotic treatment. Mortality remained higher at 6 months and 1 year long after the infection resolved but was associated mainly with co-morbidity.

Peer Review reports

Introduction

Urinary tract infection (UTI) is one of the most common bacterial infections acquired both in the community and in hospitalized patients. Gram-negative Enterobacteriaceae including Escherichia coli, Klebsiella pneumonia and Proteus mirabilis, among others, cause most infections. Of these, E. coli is the most common pathogen accounting for 75–90% of urinary isolates [1]. Other less common pathogens include Pseudomonas aeruginosa, Enterococcus spp. and Staphylococcus spp. [1].

Over the past few decades, resistant Gram-negative bacteria have emerged, resulting in an increased burden on the health care system. Enterobacteriaceae resistance is mainly conferred by extended spectrum β-lactamases (ESBL) which are plasmid mediated enzymes capable of hydrolyzing the amide bond in the ß -lactam ring of antibiotics, resulting in multiple drug resistance (MDR) to earlier generations of penicillins and most cephalosporins [2].

In the past, according to the Clinical and Laboratory Standards Institute (CLSI), ESBL producing bacteria were identified by complicated phenotypic testing. As of 2010, laboratories moved to defining extended resistance according to the minimum inhibitory concentration (MIC) of Enterobacteriaceae to ceftriaxone. It is generallly accepted that a ceftriaxone MIC of 1 μg/ml or greater is ideal for detecting ESBL producing bacteria [3,4,5] but this method oversetimates ESBL cases as some bacteria have other mechanisms of resistance [6, 7].

UTI with E. coli is a common source of bacteremia [8]. Infections with ESBL organisms are associated with increased length of hospital stay, worse outcomes and increased mortality [9]. They are also associated with increased health costs [10].

The term "urosepsis" refers to an infection that originates in the urogenital system. About 30% of sepsis cases originate from the urinary system and are mainly caused by obstruction of the urinary tract by kidney stones, enlarged prostate in men, and malignancies [11].

Before starting empiric antibiotic therapy, the patient's risk factors for sepsis with E.coli resistant to 3rd generation cephalosporins should be evaluated and the empricial treatment chosen accordingly. Antibiotics choice is adjusted once the antibiogram is available [12].

Urosepsis is a serious and life-threatening illness. In 5% of the cases, the patients progress to sepsis, multi-system organ failure and septic shock [13]. The mortality rate in these patients can reach 40%. When the bacteria causing the infection is resistant to 3rd generation cephalosporins, there is a higher chance of administering inappropriate therapy that may adversely affect outcomes.

The study objective was to compare the 30-day 6-months and 1 year mortality rate among patients with sepsis-derived urinary tract infection caused by E. coli susceptible to 3rd generation cephalosporins (EC-C) versus E. coli resistant to 3rd generation cephalosporins (EC-RC) and to assess the impact of resistance on outcomes. The study was approved by E. Wolfson Internal Review Board (0035-20-WOMC) and we received a waiver from informed consent.

Methods

This was a retrospective study involving patients who were admitted to Wolfson Medical Center from 2014 to 2019 (January 2014 until December 2019). We received the list of all patients during this period with positive E. coli urine and blood cultures from the hospital’s microbiology laboratory database. Data was collected by accessing the patients' medical files through the hospital’s computer programs. Mortality up to 30 days, 60 days, 180 days, and 1 year was assessed by the mortality registry update, received monthly by the hospital's registry.

To be included patients had to have a positive blood culture with E. coli and a positive urine culture up to 48 h before or after the time blood culture was taken and to have a diagnosis of urosepsis in their medical file. Patients with an alternative reason for sepsis were excluded. We also excluded patients who died in the first 24 h after taking the blood culture as death may not be related to antibiotic resistance.

A predefined tabular questionnaire was used to complete data collection. The questionnaire included socio-demographic details, patient comorbidities, length of hospital stay, risk factors for urosepsis, risk factors for antibiotic resistance, hospital course, antibiotic treatment, and outcome. The Charlson score [14] was used to assess co-morbidity. We also used the Pitt bacteremia score (PBS) [15] to predict patients' outcomes.

Empiric antibiotic therapy was defined as treatment given for the first 72 h from taking the culture. Specific therapy was defined as antibiotic treatment given more than 72 h after the culture was taken. Appropriate therapy was defined as an antibiotic that the E. coli isolate was susceptible according to the microbiology laboratory tests (disk diffusion or E test or VITEK according to CLSI guidelines). If the patient received at least 24 h of appropriate treatment in the first 72 h treatment was considered appropriate.

Sensitivity to ceftriaxone as a representative of 3rd generation cephalosporines was defined as an MIC ≤ 1 µg/ml or disk zone diameter ≥ 23 mm. None of the patients received ceftazidime. During the study period the treatment of choice for patients presenting with urosepsis to the emergency department and considered to be low risk for having an infection with resistant pathogens (ESBL, Enterobacteriaceae with resistance to 3rd generation cephalosporines, or other resistant bacteria) was ceftriaxone or gentamicin. For patients with suspected resistant pathogens the protocol recommends amikacin, or piperacillin-tazobactam, or ertapenem.

Statistics

Data were stored on an Excel spreadsheet (Microsoft, USA) and analysed using SPSS software v25 (IBM Inc.). Simple descriptive statistics, including means, medians, standard deviations (SD), and interquartile ranges, were used to describe the population. P value < 0.05 was considered significant. Patients with E. coli bacteremia sensitive to ceftriaxone (EC-SC) were compared to patients with bacteremia due to E. coli resistant to ceftriaxone (EC-RC). Comparisons were performed using Chi square test for categorical variables and Student’s t-test for continuous variables. A backwards conditional logistic regression model was created where the dependent variable was mortality. Candidate variables were chosen from the variable list. To enter the model, the association with the dependent variable was set at P < 0.1. We also performed Kaplan Meier with Log Rank analysis and Cox regression analysis to assess survival at 30 days, 180 days and 1 year. Hazard ratio (HR) and 95% confidence intervals (CI) were computed.

Results

We identified 322 adult patients admitted Wolfson Medical Center over a period of 6years (2014–2019) with E. coli bacteraemia that fitted the inclusion criteria. Nine patients were excluded because they died in the first 24 h after taking the first blood culture thus the study included 313 patients. All were hospitalized in internal wards. Of these, 195 (62.3%) patients with the diagnosis of urosepsis caused by E. coli susceptible to 3rd generation cephalosporins (EC-SC group) and 118 (37.7%) patients with urosepsis caused by E. coli resistant to 3rd generation cephalosporin (EC-RC group).

Patients' characteristics are presented in Table 1.

Table 1 Characteristics of patients with E. coli urosepsis
Full size table

The cohort consisted of 117 males (36%) and 205 females (74%). The mean age of the patients was 79 (SD 12) years with a mean hospitalization stay of 11 (SD 9) days. Patients' characteristics are presented in Table 1. In the EC-RC group patients were more debilitated, a third resided in nursing homes and the mean Charlson score was 5.74 vs. the EC-SC group, where only 9.1% resided in nursing homes, and the mean Charlson score was 4.93. Of note, benign prostatic hypertrophy (BPH) was more common in the EC-RC group as was a permanent urinary catheter. Patients in the EC-RC group had a higher rate of recurrent urinary tract infections.

The distribution of EC-RC by year can be seen in Fig. 1. The rate of resistant pathogens peaked in 2016 declined and then slightly increased again in 2019.

Fig. 1
figure 1

Distribution of EC-RC by year. Distribution is presented as absolute cases per year

Full size image

Table 2. describes the vitals and laboratory blood test at the day of the first positive culture. Patients in the EC-RC group had higher white blood cell (WBC) counts, and more positive blood cultures (more blood cultures were taken in this group due to a loer response rate to treatment). The Pitt bacteraemia score was similar in both groups.

Table 2 Vitals and laboratory blood tests
Full size table

Patients in the EC-RC group received longer antibiotic courses [8.20 (SD 2.80) vs. 7.40 (2.16) days, P = 0.005], as presented in Table 3. Appropriate empiric antibiotic therapy was initiated in 245 patients (78.3%), all patients in the EC-SC group but only 50 patients (42.4%) in the EC-RC group. Inappropriate treatment was mostly related to treatment with all classes of cephalosporines (67 cases, of these 66 cases received ceftriaxone), gentamicin (one case), ciprofloxacin (two cases), trimethoprim-sulfamethoxazole (one case) and piperacillin-tazobactam (one case). All isolates were sensitive to amikacin. Only two patients failed to receive appropriate antibiotic therapy after 72 h once the bacteria were identified and antibiotic susceptibilities were available.

Table 3 Hospital course and outcomes of patients with E. coli urosepsis
Full size table

Urosepsis complications were more common in the EC-RC group. Septic shock occurred more commonly in the EC-RC group. There was no difference between the groups in the need for surgical drainage or mechanical ventilation.

Thirty-day mortality occurred in 27 (8.6%) patients, 11 (5.6%) in the EC-SC group and 16 (13.6%) in the EC-RC group, P = 0.016. 60-day mortality increased to 37 (11.8%) patients [14 (7.2%) in EC-SC group vs. 23 (19.5%) in the EC-RC group, P = 0.001], 180-day mortality increased to 50 (16%) [22 (11.3%) vs 28 (23.7%), respectively, P = 0.004]. One year mortality occurred in 55 (17.6%) patients, 25 (12.8%) in the CS group and 30 (25.4%) in the EC-RC group (P = 0.005). In a logistic regression, predictors of 30-day mortality were the Charlson score, the Pitt bacteremia score, and infection with a E. coli resistant to 3rd generation cephalosporins. Appropriate antibiotic treatment was not significantly associated with 30-day mortality (Table 4). Six months mortality remained significantly higher in the EC-RC group and more than doubled in this group compared to the 30 days death rate. Increase in mortality at 1 year compared to 6 months was much smaller.

Table 4 Logistic regression of 30 days mortality
Full size table

In a logistic regression, predictors of 1 year mortality were the Charlson score, CRP levels, acute renal failure, and infection with E. coli resistant to 3rd generation cephalosporins. (Table 5). Figures 2, and 3 depict the mortality over time comparing patients with EC-SC and patients with EC-RC in a Cox regression model adjusted for age gender, and Charlson score. 30 day mortality was significantly higher in the EC-RC group (Kaplan Meier log rank P = 0.017). In the Cox survival analyses Charlson score was significantly associated with 30-day mortality [hazard ratio (HR) 1.318 95% confidence interval (CI) 1.121–1.548]. At 180 days, mortality remained significantly higher in EC-RC group (Fig. 2) (Kaplan Meier log rank P = 0.003). In the Cox survival analyses Charlson score was significantly associated with 180-day mortality (HR 1.168 95% CI 1.022–1.335]. Results were similar at 1 year with mortality remaining significantly higher in EC-RC group (Fig. 3) (Kaplan Meyer log rank P = 0.004). In the Cox survival analyses Charlson score was significantly associated with 1-year mortality (HR 1.162 95% CI 1.024–1.320].

Table 5 Logistic regression of one year mortality
Full size table
Fig. 2
figure 2

Cox regression of survival at 6 months. Time (days)—time to death at 180 days. Candidate variables were age, gender and Charlson score. Difference in mortality was significant between the two groups (Kaplan Meier log rank P = 0.003). In the Cox survival analyses Charlson score was significantly associated with 180-day mortality (HR 1.168 95% CI 1.022–1.335]

Full size image
Fig. 3
figure 3

Cox regression of survival at one year. Time (days)—time to death at 1-year. Candidate variables were age, gender and Charlson score. Results were similar at one year with mortality remaining significantly higher in EC-RC group (Kaplan Meier log rank P = 0.004). In the Cox survival analyses Charlson score was significantly associated with 1-year mortality (HR 1.162 95% CI 1.024–1.320]

Full size image

Discussion

In this study, we demonstrated that patients with EC-SC urosepsis had a more indolent course of disease with better outcomes and mortality rate than patients with EC-RC urosepsis. Patients with E. coli urosepsis were elderly with a high Charlson score. Mortality rate in the year after the infection was high in both groups but peaked to 25.4% in the EC-RC group. After adjusting for age and co-morbidities the difference in mortality was not significant.

Following the increasing prevalence of resistant Enterobactereceae causing urosepsis several studies tried to identify and deremine risk factors for acquired infections with resistant pathogens and in particulatr Enterobacterecae resistant to 3rd generation cephalopsporins (formerly described as ESBL). Several risk factors were suggestedincluding older age, reccurent UTI, previous ESBL infections, use of third generation cephalosporins or fluoroquinolones in the previous three months, prior hospitalization, recent transfer from another health care institution, Charlson comorbidity score ≥ 4, and recent urinary catheterization or procedure [15,16,17,18,19,20].

Risk factors found to be significantly associated with EC-RC urosepsis in this study were gender, permanent nursing institution patients, a higher Charlson score, BPH, chronic renal failure, a history of recurrent UTIs, previous outpatient antibiotic therapy for UTI, and previous hospitalizations with urosepsis due to Enterobacteriaceae resistant to 3rd generation cephalosporins.

Urosepsis is the second most common cause of septic shock and is more prevalent in men [13]. The EC-RC group consisted predominantly of femaes (63%), in comparison to the EC-SC group which did not differ numerically between genders. Females may be more prone to reccurent UTIs, which further increases the risk for antibiotic resistant E. coli. [21].

One study showed that patients with E. coli ESBL urosepsis had milder disease manifestation than patients with E. coli susceptible to 3rd generation cephalosporins urosepsis [22] and most studies suggested that the in hospital and 30-day mortality was not affected by 3rd generation cephalosporin resistance [23, 24]. In this study 30-day mortality was significantly higher in the EC-RC group, and more than half of the patients in the EC-RC group received empirical inappropriate antibiotic therapy. Differences in mortality between the two groups persisted up to 1 year after the bacteremia. In a multivariate logistic regression inappropriate antibiotic treatment was not significantly associated with 30-day mortality. Charlson score was significantly associated with mortality at 180 days and 1 year after the infection. Although differences between the two groups regarding mortality remained up to 1 year after the infection most of the difference between the groups occurred in the first month after the infection. Two meta analyses showed that high mortality rates associated with ESBL bacteremia were thought to result from delayed appropriate antibiotic therapy rather than the high virulence of ESBL strains [7, 25]. As patients suffering from urosepsis are elderly with many co-morbidities it may be difficult to separate these factors from the effect of resistant pathogens and the effect of inappropriate treatment, and to correctly identify all confounders. Not many studies assessed long term outcomes of resistant E. coli infections. In a study from Sweden [26] there was no difference in mortality rates 1 year after the infection between patients with ESBL pathogens compared to patients without ESBL resistance. Patients in this cohort were 4–6 years younger than the patients in our study. Thirty-day mortality in our cohort was 8.6%. In the Swedish cohort mortality was higher and reached 15% [26], in a French cohort mortality was 9.5% [27], and in an American cohort between 8 and 12% [28]. Higher mortality rates have been observed when assessing other Enterobacteriaceae causing urosepsis such as K. pneumonia. These isolates have a higher chance of being resistant to 3rd generation cephalosporins. In a report by Lee et al. [29] mortality from urosepsis due to E. coli was 7.8% versus 15% in patients with urosepsis due to K. pneumonia. Mortality is most probably related to the rate of resistant pathogens and the fact that in our cohort we did not have patients with E. coli resistant to carbapenems.

Most isolates in our study were sensitive to amikacin. We recently demonstrated that specific therapy with amikacin in patients not in septic shock and with creatinine clearance above 30 ml/min is safe and effective [30]. It was recently also shown that an institutional aminoglycoside-based regimen as empirical treatment of patients with pyelonephritis is safe and effective [31]. As drug resistance rates are rising both in the community and within hospitals [32, 33] it is important to choose correctly appropriate empirical regimens.

This study has several caveats. As data was gathered retrospectively information was limited to the patient’s follow up and physician’s notes. Therefore, information about past medical history of recurrent UTI and antibiotic therapy as outpatients may have been missed. We included only one medical center, thus resistant rates and patient population may differ between centers.

To conclude, mortality in patients with urosepsis due to E. coli is highly affected by age and comorbidities. Although mortality was higher in the EC-RC group, we could not demonstrate an association with inappropriate empirical antibiotic treatment. Mortality remained higher at 6 months and 1 year after the infections in the EC-RC group but was mostly related to differences in co-morbidities between patients with susceptible and resistant E. coli. Infection with EC-RC is associated with an increased death rate after the primary infections has resolved. Further study is warranted to better understand the factors affecting this increased death rate.

Availability of data and materials

Data can be obtained upon request from Dr. Yasmin maor.

References

  1. Hoban DJ, Nicolle LE, Badal R, et al. Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009–2010. Diagn Microbiol Infect Dis. 2011;70:507–11.

    Article  Google Scholar 

  2. Huang YWY, Alleyne A, Leung V, et al. Urosepsis due to extended-spectrum β-lactamase-producing Escherichia coli: a retrospective, single-centre review of risk factors and clinical outcomes. Can J Hosp Pharm. 2018;71:119–27.

    PubMed  PubMed Central  Google Scholar 

  3. Hawser SP, Badal RE, Bouchillon SK, et al. Comparison of CLSI 2009, CLSI 2010 and EUCAST cephalosporin clinical breakpoints in recent clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca from the SMART Global Surveillance Study. Int J Antimicrob Agents. 2010;36:293–4.

    Article  CAS  Google Scholar 

  4. M100-S25: Performance standards for antimicrobial susceptibility testing. 30th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2020.

  5. Huang Y, Carroll KC, Cosgrove SE, et al. Determining the optimal ceftriaxone MIC for triggering extended-spectrum β-lactamase confirmatory testing. J Clin Microbiol. 2014;52:2228–30.

    Article  CAS  Google Scholar 

  6. Bhalodi AA, Magnano P 3rd, Humphries RM. Performance of ceftriaxone susceptibility testing on the Accelerate Pheno® system of ESBL-producing isolates. Diagn Microbiol Infect Dis. 2020;98(4): 115171.

    Article  CAS  Google Scholar 

  7. Kohner PC, Robberts FJ, Cockerill FR 3rd, Patel R. Cephalosporin MIC distribution of extended-spectrum-{beta}-lactamase- and pAmpC-producing Escherichia coli and Klebsiella species. J Clin Microbiol. 2009;47(8):2419–25.

    Article  CAS  Google Scholar 

  8. Rodríguez-Baño J, Navarro MD, Romero L, et al. Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis Off Publ Infect Dis Soc Am. 2006;43:1407–14.

    Article  Google Scholar 

  9. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother. 2007;60:913–20.

    Article  CAS  Google Scholar 

  10. Saltoglu N, Karali R, Yemisen M, et al. Comparison of community-onset healthcare-associated and hospital-acquired urinary infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and antimicrobial activities. Int J Clin Pract. 2015;69:766–70.

    Article  CAS  Google Scholar 

  11. Yamamichi F, Shigemura K, Kitagawa K, et al. Shock due to urosepsis: a multicentre study. Can Urol Assoc J. 2017;11:E105–9.

    Article  Google Scholar 

  12. Wagenlehner FME, Pilatz A, Weidner W, et al. Urosepsis: overview of the diagnostic and treatment challenges. Microbiol Spectr. 2015;3.

  13. Wagenlehner FM, Lichtenstern C, Rolfes C, Mayer K, Uhle F, Weidner W, Weigand MA. Diagnosis and management for urosepsis. Int J Urol. 2013;20(10):963–70.

    PubMed  Google Scholar 

  14. Radovanovic D, Seifert B, Urban P, et al. Validity of Charlson Comorbidity Index in patients hospitalised with acute coronary syndrome. Insights from the nationwide AMIS Plus registry 2002–2012. Heart. 2014;100:288–94.

  15. Al-Hasan MN, Lahr BD, Eckel-Passow JE, et al. Predictive scoring model of mortality in Gram-negative bloodstream infection. Clin Microbiol Infect. 2013;19:948–54.

    Article  CAS  Google Scholar 

  16. Goyal D, Dean N, Neill S, et al. Risk factors for community-acquired extended-spectrum beta-lactamase-producing enterobacteriaceae infections—a retrospective study of symptomatic urinary tract infections. Open Forum Infect Dis. 2019;6:ofy357.

    Article  Google Scholar 

  17. Tumbarello M, Trecarichi EM, Bassetti M, et al. Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. Antimicrob Agents Chemother. 2011;55:3485–90.

    Article  CAS  Google Scholar 

  18. Augustine MR, Testerman TL, Justo JA, et al. Clinical risk score for prediction of extended-spectrum β-lactamase-producing enterobacteriaceae in bloodstream isolates. Infect Control Hosp Epidemiol. 2017;38:266–72.

    Article  Google Scholar 

  19. Goodman KE, Lessler J, Cosgrove SE, et al. A clinical decision tree to predict whether a bacteremic patient is infected with an extended-spectrum β-lactamase-producing organism. Clin Infect Dis Off Publ Infect Dis Soc Am. 2016;63:896–903.

    Article  CAS  Google Scholar 

  20. Chopra T, Marchaim D, Johnson PC, et al. Risk factors for bloodstream infection caused by extended-spectrum β-lactamase–producing Escherichia coli and Klebsiella pneumoniae: a focus on antimicrobials including cefepime. Am J Infect Control. 2015;43:719–23.

    Article  CAS  Google Scholar 

  21. Al-Badr A, Al-Shaikh G. Recurrent urinary tract infections management in women. Sultan Qaboos Univ Med J. 2013;13(3):359–67.

    Article  Google Scholar 

  22. Skippen I, Shemko M, Turton J, et al. Epidemiology of infections caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp: a nested case–control study from a tertiary hospital in London. J Hosp Infect. 2006;64:115–23.

    Article  CAS  Google Scholar 

  23. Leistner R, Bloch A, Gastmeier P, et al. E. coli bacteremia in comparison to K. pneumoniae bacteremia: influence of pathogen species and ESBL production on 7-day mortality. Antimicrob Resist Infect Control. 2016;5:37.

    Article  CAS  Google Scholar 

  24. Rottier WC, Ammerlaan HSM, Bonten MJM. Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis. J Antimicrob Chemother. 2012;67:1311–20.

    Article  CAS  Google Scholar 

  25. Ryan J, McLornan L, O’Neill E. The impact of increasing antimicrobial resistance in the treatment of urosepsis. Ir J Med Sci. 1971;2019(189):611–5.

    Google Scholar 

  26. Richelsen R, Smit J, Schønheyder HC, Laxsen Anru P, Gutiérrez-Gutiérrez B, Rodríguez-Bãno J, Nielsen H. Outcome of community-onset ESBL-producing Escherichia coli and Klebsiella pneumoniae bacteraemia and urinary tract infection: a population-based cohort study in Denmark. J Antimicrob Chemother. 2020;75(12):3656–64.

    Article  CAS  Google Scholar 

  27. de Lastours V, Laouénan C, Royer G, Carbonnelle E, Lepeule R, Esposito-Farèse M, Clermont O, Duval X, Fantin B, Mentré F, Decousser JW, Denamur E, Lefort A. Mortality in Escherichia coli bloodstream infections: antibiotic resistance still does not make it. J Antimicrob Chemother. 2020;75(8):2334–43.

    Article  Google Scholar 

  28. Mark DG, Hung YY, Salim Z, Tarlton NJ, Torres E, Frazee BW. Third-generation cephalosporin resistance and associated discordant antibiotic treatment in emergency department febrile urinary tract infections. Ann Emerg Med. 2021;78(3):357–69.

    Article  Google Scholar 

  29. Lee CC, Lee CH, Hong MY, Hsieh CC, Tang HJ, Ko WC. Propensity-matched analysis of the impact of extended-spectrum β-lactamase production on adults with community-onset Escherichia coli, Klebsiella species, and Proteus mirabilis bacteremia. J Microbiol Immunol Infect. 2018;51(4):519–26.

    Article  CAS  Google Scholar 

  30. Zohar I, Schwartz O, Yossepowitch O, et al. Aminoglycoside versus carbapenem or piperacillin/tazobactam treatment for bloodstream infections of urinary source caused by Gram-negative ESBL-producing Enterobacteriaceae. J Antimicrob Chemother. 2020;75:458–65.

    CAS  PubMed  Google Scholar 

  31. Elbaz M, Zadka H, Weiss-Meilik A, Ben-Ami R. Effectiveness and safety of an institutional aminoglycoside-based regimen as empirical treatment of patients with pyelonephritis. J Antimicrob Chemother. 2020;75(8):2307–13.

    CAS  PubMed  Google Scholar 

  32. Ardá V, Trick WE, Zhang H, Schwartz DN. Spatial, ecologic, and clinical epidemiology of community-onset, ceftriaxone-resistant enterobacteriaceae, cook county, Illinois, USA. Emerg Infect Dis. 2021;27(8):2127–34.

    Article  Google Scholar 

  33. Tamma PD, Smith TT, Adebayo A, Karaba SM, Jacobs E, Wakefield T, Nguyen K, Whitfield NN, Simner PJ. Prevalence of blaCTX-M Genes in Gram-Negative Bloodstream Isolates across 66 Hospitals in the United States. J Clin Microbiol. 2021;59(6):e00127-e221.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

None.

Funding

The study was funded by internal funds of the Infectious Disease Unit.

Author information

Authors and Affiliations

  1. Department of Medicine C, Wolfson Medical Center, Holon, Israel

    Milena Tocut

  2. Infectious Disease Unit, Wolfson Medical Center, 62 Halochamim Street, 58100, Holon, Israel

    Iris Zohar, Orit Yossepowitch & Yasmin Maor

  3. Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

    Milena Tocut, Iris Zohar & Yasmin Maor

  4. Microbiology and Immunology Laboratory Wolfson Medical Center, Holon, Israel

    Orna Schwartz

Authors
  1. Milena Tocut
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Iris Zohar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Orna Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Orit Yossepowitch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yasmin Maor
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MT writing draft, data acquisition, data cleaning; IZ conceptualization, comments on final draft; OS laboratory data acquisition, comments on final draft; OY comments on final draft; YM conceptualization, statistical analysis, writing final version. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Yasmin Maor.

Ethics declarations

Ethics approval and consent to participate

This study was approved by E. Wolfson Institutional Review Board (approval no: 0035-20-WOMC) and included a waiver of informed consent due to the retrospective nature of this study. The study was performed according to the Declaration of Helsinki. Data was obtained from the hospital registry.

Consent for publication

Not Applicable as there is no identifiable information (image, face, name etc.) of participant is revealed in the submission.

Competing interests

We declare that the authors have no competing interests as defined by BMC, or other interests that might be perceived to influence the results and/or discussion reported in this paper. Yasmin Maor received an educational grant and lecture fees from Pfizer and lecture fees from MSD. Milena Tocut, Iris Zohar, Orna Schartz, and Orit Yossepowitch have no conflict of interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tocut, M., Zohar, I., Schwartz, O. et al. Short- and long-term mortality in patients with urosepsis caused by Escherichia coli susceptible and resistant to 3rd generation cephalosporins. BMC Infect Dis 22, 571 (2022). https://doi.org/10.1186/s12879-022-07538-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12879-022-07538-5

Keywords

  • Escherichia coli
  • ESBL
  • Resistance
  • Mortality

BMC Infectious Diseases

ISSN: 1471-2334

Contact us